Ignite Creation Date:
2024-05-06 @ 1:01 PM
Last Modification Date:
2024-10-26 @ 1:07 PM
Study NCT ID:
NCT03910712
Status:
UNKNOWN
Last Update Posted:
2019-04-10
First Post:
2019-04-03
Brief Title:
Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive HR Positive MBC
Sponsor:
Peking Union Medical College Hospital
Organization:
Peking Union Medical College Hospital
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Hormone Receptor Positive Tumor |
| Breast Cancer Female |
| HER2-positive Breast Cancer |
| Hormone Receptor Positive Malignant Neoplasm of Breast |
| Metastatic Breast Cancer |
| Breast Diseases |
Keywords:
| Name | View |
|---|---|
| MBC Pyrotinib Trastuzumab First line HER2 | View |